Halozyme Therapeutics Inc.
HALO
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.83B
Close$
$115.69
10.3% upside
Current Fair Value
10.3% upsideUndervalued by 10.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.83 Billion |
|---|---|
| Enterprise Value | $14.81 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.64 |
| Beta | 0.85 |
| Outstanding Shares | 117,274,000 |
Return
| Return on Equity | 288.13% |
|---|---|
| Return on Assets | 16.05% |
| Return on Invested Capital | 42.54% |
Valuation & Multiples
| P/E Ratio | 30.73 |
|---|---|
| PEG | 78.38 |
| Price to Sales | 7.49 |
| Price to Book Ratio | 104.89 |
| Enterprise Value to Revenue | 8.9 |
| Enterprise Value to EBIT | 15.6 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 14.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.79
Average shareholder expectationRevenue Estimate
$402.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$2.11
Average shareholder expectationRevenue Estimate
$482.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6167▼ 16.33% |
|---|---|
| Total Calls | 450,800▲ 41.32% |
| Total Puts | 278,000▲ 11.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 104.85%▲ 2.89% |
|---|---|
| Total Invested | $9.79B▲ 25.75% |
| Investors Holding | 666▲ 15.00% |
ESG Score
No data
About Halozyme Therapeutics Inc.
CEO: Helen Torley